Corbus Pharmaceuticals shares surge 12.86% premarket on clinical progress in obesity and oncology pipelines.

Corbus Pharmaceuticals surged 12.86% in premarket trading following positive clinical updates and financial stability. The company reported progress in its oncology and obesity drug pipelines, including favorable safety data and early weight-loss signals from CRB-913 in Phase 1a trials for obesity. Additionally, Corbus highlighted a $73.8 million capital raise in November 2025, securing $173 million in cash to fund operations through 2028. These developments, coupled with routine insider sales deemed non-concerning, reinforced investor confidence in the firm’s ability to advance its therapies and sustain operations, driving the premarket rally.